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Basal interferon signaling and 
therapeutic use of interferons in 
controlling rotavirus infection 
in human intestinal cells and 
organoids
Mohamad S. Hakim1,2, Sunrui Chen1, Shihao Ding1, Yuebang Yin1, Aqsa Ikram1,3, Xiao-xia Ma4, 
Wenshi Wang1, Maikel P. Peppelenbosch1 & Qiuwei Pan  1
Rotavirus (RV) primarily infects enterocytes and results in severe diarrhea, particularly in children. 
It is known that the host immune responses determine the outcome of viral infections. Following 
infections, interferons (IFNs) are produced as the first and the main anti-viral cytokines to combat the 
virus. Here we showed that RV predominantly induced type III IFNs (IFN-λ1), and to a less extent, type 
I IFNs (IFN-α and IFN-β) in human intestinal cells. However, it did not produce detectable IFN proteins 
and thus, was not sufficient to inhibit RV replication. In contrast, we revealed the essential roles of the 
basal IFN signaling in limiting RV replication by silencing STAT1, STAT2 and IRF9 genes. In addition, 
exogenous IFN treatment demonstrated that RV replication was able to be inhibited by all types of 
IFNs, both in human intestinal Caco2 cell line and in primary intestinal organoids. In these models, IFNs 
significantly upregulated a panel of well-known anti-viral IFN-stimulated genes (ISGs). Importantly, 
inhibition of the JAK-STAT cascade abrogated ISG induction and the anti-RV effects of IFNs. Thus, 
our study shall contribute to better understanding of the complex RV-host interactions and provide 
rationale for therapeutic development of IFN-based treatment against RV infection.
Rotavirus (RV) is a member of the Reoviridae family that primarily infects mature enterocytes of the small intes-
tinal villi. However, it can spread systematically to cause viremia and infect multiple organs1. RV is the most 
frequent agent of severe dehydrating diarrhea episodes in children under five years of age2. Before introduction of 
RV vaccines, RV caused 9.8 billion of severe diarrhea episodes and 1.9 billion diarrhea-related deaths worldwide, 
with the highest burden in southeast Asian and African countries3. The incidence is lower especially in countries 
that have introduced oral RV vaccination4.
Innate immune responses are the first line defenses critical to battle RV infection5. Recognition of RV viral 
proteins and double-stranded RNA by the host induces the production of cytokines, including interferons 
(IFNs)6. IFNs are potent anti-viral cytokines classified into three different groups, type I (IFN-α, IFN-β, IFN-δ, 
and others), type II (IFN-γ) and type III (IFN-λ1, IFN-λ2 and IFN-λ3) IFNs7,8. Some members are widely used 
in the clinic for treating viral infections or malignancy; whereas others are at stages of clinical development. Even 
though they bind to distinct receptors, they signal through a common, classical Janus kinase signal transducer 
and activator of transcription (JAK-STAT) pathway8,9.
Once activated, STAT1 and STAT2 are phosphorylated and bind IFN regulatory factor 9 (IRF9) to form IFN 
stimulated gene factor 3 complex (ISGF3). ISGF3 subsequently translocates to the nuclues, leading to induced 
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transcription of hundreds IFN-stimulated genes (ISGs) which cooperatively establish an anti-viral state against 
various types of viruses10. Furthermore, IFN induction following RV recognition is essential to promote the 
development of adaptive, B-cell mediated immune responses11. On the other hand, however, RV has developed 
effective strategies to evade the host immune response12. RV can inhibit IFN production in the infected cells13 and 
also block the action of STAT1 and STAT2 proteins14. Viral nonstructural protein NSP1-mediated IFN inhibition 
has been shown to be associated with different levels of RV replication in primary mouse cells15.
Detectable levels of IFN-α16 and IFN-γ17,18 were documented in chidlren with acute RV diarrhea, suggest-
ing their roles in the disease pathogenesis. Indeed, early in vitro19–21 and animal studies in calves22 and piglets23 
demonstrated anti-RV effects of both type I and II IFNs. However, in the murine models of homologous RV 
infection, administration of type I (IFN-α and IFN-β) and II (IFN-γ) IFNs failed to protect the mice against RV 
infection24. In addition, mice deficient in type I or II IFN receptor signaling controlled RV infection as wild-type 
mice24,25. These results suggest a minor role of type I and II IFNs in controlling RV infection in mice. Interestingly, 
a more prominent role of type III IFNs was demosntrated in the mouse model25,26. Administration of IFN-λ con-
ferred better protection against RV infection than IFN-α/β25.
Because animal models do not always recapitulate the responsiveness in human, we therefore comprehen-
sively assessed the role of endogenous and the therapeutic IFNs on RV infection in human intestinal cell line and 
primary intestinal organoids. We found that the basal JAK-STAT cascade is effective in restraining RV infection. 
Furthermore, RV is sensitive to inhibition by all three types of IFNs in both models. Our results strengthen the 
evidence of essential roles of IFN pathway in protecting the host against viral infection.
Results
RV infection modulates IFN gene expression. First, we investigated whether RV SA11 modulates the 
expression of the three types of IFN genes. Human intestinal Caco2 cells were infected with RV SA11 for 48 hours. 
An effective replication was shown by an increase in intracellular RNA level as well as secreted rotavirus in culture 
medium (Supplementary Fig. S1). In addition, immunofluorescence staining showed VP6-positive Caco2 cells at 
48 hours after infection, indicating productive replications (Supplementary Fig. S2).
Relative RNA levels of ifna, ifnb, ifng, il29 (IFN-λ1) and il28 (IFN-λ2/IFN-λ3) genes were examined and com-
pared to uninfected cells at 6, 24, 36 and 48 hours post infection. As shown in Fig. 1, RV infection had no major 
effect on the gene expression at 6 and 24 hours post-infection. At 36 hours after infection, only il29 gene expres-
sion was notably increased by 3.4 ± 1.0 (P < 0.05) fold. Importantly, at 48 hours after infection, the expression of 
ifna and ifnb genes were significantly increased by 2.8 ± 0.6 (P < 0.001) and 2.8 ± 0.5 (P < 0.01) fold, respectively. 
A profound upregulation was observed on il29 by 29.6 ± 10.7 fold (P < 0.001). No difference was found on il28 
gene expression. The expression level of ifng gene was undetectable (data not shown). Together, our findings 
showed that RV SA11 infection preferentially induced il29 (IFN-λ1) gene expression in Caco2 cells.
The increased expression of IFN genes does not result in production of detectable IFN protein 
and was not sufficient to limit RV SA11 replication. To examine whether the increased expression of 
IFN genes result in IFN production in our cell culture system, we collected the conditioned medium (superna-
tant) derived from control and SA11-infected Caco2 cells at 48 hours post-infection. Then, we performed IFN 
production bioassay by adding the conditioned medium into two highly IFN sensitive cell lines, Huh7-based 
ISRE-luciferase and HCV-luciferase reporter cell lines. As shown in Fig. 2A, the supernatant from SA11-infected 
Caco2 cells was not capable of stimulating ISRE reporter, while as low as 1 U/mL of IFN-α significantly induced 
ISRE-luc by 1.8 ± 0.2 fold (P < 0.001). Consistently, it was not able to diminish HCV replication, although as low 
as 0.1 IU/mL of IFN-α considerably reduced HCV-luc by 40 ± 7% fold (P < 0.001) (Fig. 2B).
The induced expression of IFN-α and IFN-λ1 proteins can signal via autocrine and paracrine manner to 
stimulate ISGs expression. Therefore, to confirm our previous findings from ISRE-luciferase cell lines, we also 
examined ISG expression in SA11-infected Caco2 cells. Despite a clear induction of IFN genes, we observed no 
upregulation of ISGs, both at 24 and 48 hours post-infection. At 48 hours, some ISGs were significantly downreg-
ulated by SA11 infection, including IRF1, IRF9, MX1 and IFIT3 (Fig. 2C).
To rule out the possibility that endogenous IFN produced (if any) following RV infection is sufficient to 
restrict RV replication, we investigated whether the inhibition of JAK proteins, the downstream elements of IFN 
receptor, influences RV replication. Treatment of JAK I inhibitor at 5 and 10 μM had no effect on RV replication 
(Fig. 2D). At those concentrations, the drug did not influence the cell viability as determined by MTT assay 
(Fig. 2E). Collectively, our results demonstrated that the increased expression of IFN genes during RV infection 
did not result in IFN production and consequently, was not sufficient to limit RV replication.
The basal IFN signaling is necessary to restrict RV replication. Although no functional level of IFN 
is induced by RV infection, we delineated the role of basal IFN signaling in regulating RV replication. ISGF3 that 
consists of STAT1, STAT2 and IRF9 is a central complex dictating the IFN signaling. We have previously reported 
that in the absence of IFN stimulation, unphosphorylated ISGF3 drives constitutive ISG expression in homeo-
static condition and is critical to provide immunity against hepatitis C (HCV) and E (HEV) virus infections27.
First, we transduced Caco2 cells with a lentiviral vector expressing STAT1- and STAT2-specific shRNA. A 
successful knockdown was shown in Fig. 3A,C. Supplementary Fig. S3 showed the quantification of knockdown 
efficiency. Importantly, shRNA-mediated STAT1 and STAT2 knockdown resulted in an increased RV replication 
by 3.8 ± 0.6 fold (P < 0.01) (Fig. 3B) and 13 ± 4.6 (P < 0.001) (Fig. 3D), respectively.
Next we investigated the role of IRF9. Two of three tested IRF9-specific shRNA (sh-2 and sh-3) exert a potent 
gene silencing capacity (Fig. 3E and Supplementary Fig. S3). Consistently, IRF9 KD led to 4.8 ± 1.0 fold elevation 
of RV replication as compared to sh-CTR transfected cells (P < 0.001) (Fig. 3F). Altogether, these results indicate 
that the integrity of ISGF3 complex is required to provide basal immunity against RV infections.
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RV SA11 is sensitive to IFN treatment in human intestinal Caco2 cells and primary intestinal 
organoids. Since we did not find a significant role of endogenous IFN in restricting RV replication, we then 
investigated whether RV was sensitive to exogenous IFN treatment (Fig. 4A). Treatment of SA11-infected Caco2 
cells with 100 and 1000 IU/mL of IFNα resulted in a potent inhibition of RV replication by 79 ± 4% (P < 0.001) 
and 98 ± 0.7% (P < 0.001) as measured in total RNA levels. Similarly, IFNβ treatment at 100 and 1000 IU/mL 
dose-dependently inhibited total viral RNA levels by 60 ± 9% (P < 0.01) and 73 ± 7% (P < 0.001). Type II IFNs 
also strongly reduced RV replication, although the effects were not dose-dependent. At concentration of 100 and 
1000 ng/mL, IFNγ restricted RV replication by 81 ± 6% (P < 0.001) and 68 ± 7% (P < 0.01). Analysis of intra and 
extracellular RNA levels also demonstrated the inhibition of RV replication by type I and II IFNs in Caco2 cells 
(Supplementary Fig. S4).
Next, we investigated anti-RV effects of type III IFNs. Treatment of SA11-infected Caco2 cells with 100 and 
1000 ng/mL of IFNλ1 resulted in a notable restriction of RV replication by 76 ± 11% (P < 0.01) and 65 ± 6% 
(P < 0.001). Inhibition of RV replication was also observed with IFNλ2 treatment. At concentration of 100 and 
1000 ng/mL, IFNλ2 decreased RV replication by 61 ± 17% (P < 0.01) and 50 ± 7% (P < 0.05), respectively. At a 
similar concentration, IFNλ3 significantly dimished RV replication by 52 ± 7% (P < 0.05) and 62 ± 6% (P < 0.01). 
Analysis of intra and extracellular RNA levels also demonstrated the effects of type III IFNs in limiting rotavirus 
replication in Caco2 cells (Supplementary Fig. S4).
To further confirm the effects of various types of IFNs that we observed in the conventional 2D cell culture 
system, we employed a 3D culture model of primary intestinal organoids derived from one individual (P1) to 
more closely mimick the physiological situation in vivo (Fig. 4B). Treatment of SA11-infected organoid with 
1000 IU/mL of IFNα and IFNβ led to a significant reduction of intracellular viral RNA levels by 73.9 ± 7.5% 
(P < 0.05) and 57.8 ± 7.7% (P < 0.05), respectively. Surprisingly, the inhibition by IFNγ was more pronounced. 
Treatment of SA11-infected organoid with 1000 ng/mL of IFNγ significantly reduced intracellular viral RNA 
levels by 99.5 ± 0.1% (P < 0.01) (Fig. 4C). Similarly, treatment with 1000 ng/mL of IFNλ1, IFNλ2 or IFNλ3 
Figure 1. RV infection modulates IFN gene expression in Caco2 cells. Caco2 cells were infected with RV SA11. 
Relative RNA levels of ifna, ifnb, il29 (IFN-λ1) and il28 (IFN-λ2 and IFN-λ3) genes were examined at 6, 24, 36 
and 48 hours post infection as compared to uninfected cells. Data were normalized to GAPDH and presented as 
means ± SEM. (n = 3 independent experiments with each of 3–4 replicates; **P < 0.01; ***P < 0.0001).
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significantly diminished intracellular viral RNA levels by 70.2 ± 7.6% (P < 0.01), 78.2 ± 4.2% (P < 0.01) and 
79.6 ± 3.6% (P < 0.01), respectively (Fig. 4C). Quantification of extracellular (secreted) RNA levels also showed 
a notable reduction of viral production (Supplementary Fig. S5). To confirm these findings, we obtained pri-
mary intestinal organoids from the second individual (P2). Similarly, treatment of SA11-infected organoid with 
IFNα (1000 IU/mL), IFNγ (1000 ng/mL) and IFNλ1 (1000 ng/mL) significantly reduced total viral RNA lev-
els by 74.6 ± 5.1% (P < 0.01), 85.5 ± 4.4% (P < 0.01) and 71.4 ± 10.5% (P < 0.01), respectively (Supplementary 
Fig. S6A). Collectively, these results suggest that all type of IFNs effectively inhibit RV replication, both in 2D and 
3D culture model system.
Figure 2. The increased expression of IFN genes does not result in production of detectable IFN protein and 
was not sufficient to limit RV SA11 replication. IFN production bioassay was performed in ISRE-luciferase 
(A) and HCV-luciferase (B) cell lines which are highly sensitive to IFN treatment. Conditioned medium 
derived from 48 hours post-RV infection on Caco2 cells was used (n = 3 independent experiments with each 
2–3 replicates). (C) Caco2 cells were infected with RV SA11. Relative RNA levels of IFN-stimulated genes 
(ISGs) were examined at 24 and 48 hours post-infection as compared to uninfected cells (n = 3 independent 
experiments with each 2–3 replicates). (D) Pan-JAK I inhibitor had no effects on RV replication (n = 3 
independent experiments with each 2–3 replicates). (E) Pan-JAK I inhibitor did not affect cell viability as 
determined by MTT assay (OD490 value) at 48 hours of treatment (n = 3 independent experiments with each 2 
replicates). Data were presented as means ± SEM., **P < 0.01; ***P < 0.001; ns, not significant.
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Figure 3. The key component of ISGF3 complex is necessary to restrict RV replication. (A) STAT1 knockdown 
by lentiviral shRNA vectors. Western blot analysis confirms a successful knockdown of total STAT1 protein. 
(B) Correspondingly, knockdown of STAT1 led to a significant increase of RV replication (n = 3 independent 
experiments with 3–4 replicates each). (C) Knockdwon of STAT2 by lentiviral shRNA vectors. Western blot 
analysis shows a potent decrease of total STAT2 protein level. (D) Similarly, silencing of STAT2 resulted in 
a prominent increase of RV RNA level (n = 3 independent experiments with 3–4 replicates each). (E) IRF9 
knockdwon by lentiviral shRNA vectors. Western blot analysis shows a potent decrease of IRF9 protein level. 
(F) Knockdown of IRF9 led to a notable increase of RV replication (n = 3 independent experiments with 3–4 
replicates each). Data were presented as means ± SEM., **P < 0.01; ***P < 0.001.
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Sensitivity of patient-derived RV strains to type I, II and III IFNs. Next, we evaluated the sensi-
tivity of patient-derived RV strains against different types of IFNs. We treated human RV (G1P[8]) with IFNα 
100 IU/mL (as representative of type I IFN), IFNγ 100 ng/mL (type II IFN), IFNλ1 and IFNλ3 100 ng/mL (as 
representative of type III IFN) for 48 hours. Three out of four samples were sensitive to the inhibition by IFNα 
Figure 4. Exogenous treatment of type I, II and III IFNs inhibits RV SA11 infection. Antiviral activity of 
IFNα, IFNβ, IFNγ, IFNλ1, IFNλ2 and IFNλ3 treatment against RV SA11 infection on (A) Caco2 cells (n = 2–3 
independent experiments with each of 3–4 replicates) and (C) organoids (n = 3 independent experiments with 
each of 2–3 replicates) at 48 hours after infection. Data were presented as means ± SEM., *P < 0.05; **P < 0.01; 
***P < 0.001. (B) A representative picture of the morphology of human small intestinal organoid at day 4 post 
embedding in Matrigel. The organoid used in this experiment was derived from one individual (P1).
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and all samples were inhibited by IFNγ (Fig. 5). Interestingly, only one sample which is sensitive to type III IFN 
treatment. Collectively, our data suggest that type I and II IFN more efficiently inhibit the replication of human 
RV strains as compared to type III IFN.
Induction of the known antiviral ISGs by all three types of IFNs. The observed anti-RV activity 
of type I, II and III IFNs prompted us to investigate whether all types of IFNs effectively induce the expression 
of known anti-viral ISGs in Caco2 cells and organoid. Although there are hundreds of ISGs, only a subset have 
broad or targeted antiviral effects28. We have selectively investigated the expression of those known antiviral 
ISGs. Indeed, treatment of Caco2 cells with recombinant human IFN-α (1000 IU/mL), IFN-γ (1000 ng/mL) and 
IFN-λ1 (1000 ng/mL) for 24 hours induced the expression a panel of ISGs (Fig. 6A). Similarly, they also efficiently 
induced ISGs in organoids derived from both P1 (Fig. 6B) and P2 (Supplementary Fig. S6B). Interestingly, we 
observed a variation of the type and extent of ISG induction with different IFN treatment. For example, IRF1 and 
RTP4 were more induced by IFN-γ as compared to IFN-α in Caco2 cells. In contrast, DDX60 and IFI6 were more 
induced by IFN-α as compared to IFN-γ (Fig. 6A). In organoid (P1), several ISGs were more efficiently induced 
by IFN-λ1 as compared to IFN-α and IFN-γ, including OASL, ISG15 and OAS1 (Fig. 6B).
Inhibition of JAK-STAT signaling abrogates the anti-RV activity of IFN-α and IFN-γ. The ISG 
induction by type I and III IFNs is mediated via a similar pathway involving ISGF3 complex. For type II IFN, its 
signaling pathway involves phosphorylation and dimerization of STAT1 to form IFNγ activation factor (GAF)9. 
To investigate the role of JAK-STAT signaling pathway in the anti-RV effects of IFNs, we used JAK I inhibitor that 
predominantly inhibit JAK1 protein, the upstream element that is responsible for STAT1 and STAT2 phospho-
rylation. As expected, JAK I inhibitor (10 μM) efficiently blocked IFNα- and IFNγ-induced ISG expression in 
Caco2 cells (Supplementary Figs S7 and S8). Consistently, JAK I inhibitor treatment abolished the anti-RV effects 
Figure 5. Sensitivity of patient-derived RV strains to type I, II and III IFNs. Caco2 cells were infected with four 
different patient-derived RV strains (G1P[8]) and treated with IFNα 100 IU/mL (as representative of type I 
IFN), IFNγ 100 ng/mL (type II IFN), IFNλ1 and IFNλ3 100 ng/mL (as representative of type III IFN). Distinct 
sensitivity was observed among these patient-derived RV samples. Human RV RNA levels were quantified by 
qRT-PCR at 48 hours post-infection and normalized to a reference gene GAPDH. The data are derived from an 
experiment for multiple patient-derived RV strains.
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Figure 6. ISG induction by type I, II and III IFNs on Caco2 cells and organoids. Caco2 cells (A) and organoids 
(B) were stimulated with IFNα 1000 IU/mL (as representative of type I IFN), IFNγ 1000 ng/mL (type II IFN) 
and IFNλ1 1000 ng/mL (as representative of type III IFN) for 24 hours. The expression levels of several ISGs 
were measured by qRT-PCR. The organoid used in this experiment was derived from one individual (P1).
Figure 7. JAK I inhbitor block the anti-RV effects of IFNα and IFNγ. Caco2 cells were first infected with 
RV SA11 for 60 minutes. After four times washing, IFNα or IFNγ and Pan-JAK I inhibitor were added 
simultaneously to SA11-infected Caco2 cells and then cultured for 48 hours. Pan-JAK I inhibitor (10 μM) can 
block the anti-RV effects of IFNα 100 IU/mL (A) and IFNγ 100 ng/mL (B) in Caco2 cells. (n = 3 independent 
experiments with 2–4 replicates each) Data were presented as means ± SEM., *P < 0.05; **P < 0.01; ns, not 
significant.
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of IFN-α and IFNγ in Caco2 cell lines (Fig. 7A,B, repectively). These data clearly indicate an important role of 
JAK-STAT pathway in mediating the anti-RV effects of IFNs.
Discussion
The in vitro study of RV biology was mainly based on the conventional two-dimensional (2D) cell culture sys-
tem of intestinal carcinoma-derived cell lines, including Caco2 and HT29 cell lines14,29–31. They are homogenous 
immortalized cell lines that functionally mimic the real biological processes in humans. However, they are lacking 
three-dimensional (3D) details of the human intestine in vivo32. Recently, 3D models of primary intestinal orga-
noids were developed for studying RV biology which better recapitulate the architecture and cellular composition 
of the human intestine33–35. Intestinal organoids contain heterogenous and non-transformed cell types, including 
enterocytes, enteroendocrine cells, goblet cells, Paneth cells and stem cells35. Therefore, they enable us to investi-
gate individual-specific response associated with histo-blood group antigen (HBGAs) profiles and microbiome 
diversity35.
Transcriptional analysis of SA11-infected Caco2 cells revealed that RV predominantly induced type III 
(IFNλ1) rather than type I (IFNα and IFNβ) IFN responses. In other intestinal epithelial cells, such as HT29, 
RV infection induces type I IFN response (IFNβ) and subsequently regulates ISG expression29,30,36. However, our 
findings were consistent with previous studies in human intestinal enteroids (organoids) infected with human 
RV strains in which predominant type III IFN responses (IFNλ1 and IFNλ2) were observed34. The relatively 
low induction of type I IFNs in these human epithelial cells was also consistent with studies in murine RV37. 
Following murine RV infection, type I IFN response was mainly produced by immune (hematopoietic) cells, not 
epithelial cells37. A predominant type III IFN response was also observed in hepatocyte upon HCV38 and HEV 
infection39. However, both type I and III IFN were similarly induced following influenza virus infection in lung 
epithelial cells40. Thus, all these findings suggest that preferential induction of type I and/or type III IFN response 
is virus- and cell type-specific and reflects the complex regulation of type I and III IFN induction following viral 
infections.
Despite a clear induction of type III IFN responses, our IFN production bioassay found undetectable levels of 
IFN proteins in the (conditioned) culture medium from SA11-infected Caco2 cells (Fig. 2A,B). Consistently, we 
did not observe ISG upregulation in SA11-infected Caco2 cells (Fig. 2C), indicating an absence of secreted IFN 
to stimulate ISG expression in an autocrine and/or paracrine manner. Further analysis by inhibiting downstream 
IFN signaling using JAK inhibitors demonstrated that RV replication levels were not altered. In human intestinal 
enteroids (organoids) infected with human RV strains, type III IFN induction was followed by stimulation of 
type III-dependent ISGs34. These discrepancies may be due to different RV strains as well as different cellular 
compositions of both models. However, despite this ISG induction, blockade of type I and III IFN receptor had no 
effects on RV replication34. Altogether, these findings indicate that endogenously produced IFNs (if any) were not 
sufficient to limit RV replication, eventhough they were able to induce ISGs in intestinal organoid models. These 
findings also suggest the ability of RV to subvert innate immune responses. It is known that RV have multiple 
ways to blunt innate IFN responses12. It has been shown that RV nonstructural protein 1 (NSP1) interacts with 
IRF3 to promote its degradation, leading to attenuation of IFN induction41.
While previous studies mainly focused on the role of STAT1 in RV replication15,42, here we highlighted the 
role of basal IFN signaling in constraining RV infection. Individual knockdown of ISGF3 component, i.e. STAT1, 
STAT2 and IRF9, led to an elevated level of RV replication. Similarly, STAT1 knockout (KO) mice shed a sig-
nificantly higher titer of RV than wild-type (WT) controls42. STAT1 was also shown to protect against lethal 
challenge of murine norovirus infection in mice43. In dengue virus (DENV)-infected mice, STAT2 was essentially 
required to protect against DENV-mediated diseases independently of STAT144. Our findings were also consist-
ent with our previous in vitro studies demonstrating that unphosphorylated ISGF3 complex was responsible to 
maintain basal transcription of ISGs in the absence of IFN stimulation to provide a “combat-ready” antiviral state 
in the susceptible host27. Thus, basal IFN signaling as maintained by its essential component, including STAT1, 
STAT2 and IRF9, are pivotal to restrict RV replication.
While endogenous IFN response was not able to reduce RV replication, exogenous IFN treatment was effec-
tive to limit RV replication. We demonstrated that all three types of IFNs have notable antiviral effects against 
simian RV SA11 both in Caco2 cells and human organoid. Patient-specific organoid lines have promising impli-
cations in personalized medicine. Noteworthy, our study employed organoids derived from only two individuals. 
In this aspect, using organoids derived from several numbers of patients would be much better in recapitulating 
inter-individual variations, including HBGAs profiles, microbime diversity and genetic background32,35.
We have also successfully cultivated four human-derived RV strains from acute diarrhea patients. Treatment 
with representative type I (IFNα), II (IFNγ) and III (IFNλ1 and IFNλ3) IFNs showed various sensitivity of 
human RV to IFNs, in which more pronounced inhibition was observed with type I and II rather than type III 
IFN treatment. Previous studies using human organoid models, type I IFN was more effective than type III IFN to 
suppress human RV replication34. However, conflicting results were found from in vivo studies about the relative 
contributions of type I and III IFNs during RV infections25,26,45. Type I IFN response plays a functional role to 
limit extra-intestinal spread in the mesenteric lymph node (MLN)45. On the other hand, RV has the capacity to 
attenuate the antiviral actions of IFNs14. Our study therefore suggests that human RV may differentially adapt in 
homologous host.
Since many previous studies mainly focused on type I and III IFNs, our study highlights the role of type II 
IFN (IFNγ) in limiting RV replication. Previous studies showed that IFNγ level in the serum was significantly 
higher in children with RV diarrhea than those of control children17. In our study, transcriptional analysis showed 
that IFNγ mRNA level was not detectable from SA11-infected Caco2 cells (data not shown). However, it has 
been shown that IFNγ was produced from human peripheral blood mononuclear cells (PBMCs) stimulated with 
RV46. Consistently, the level of IFNγ gene expression as well as secreted level in the supernatant of PBMCs were 
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significantly elevated in children with RV diarrhea as compared with controls18,47. These findings suggest that 
immune cells, and not epithelial Caco2 cells, were responsible for IFNγ production upon RV infection.
RV-specific CD4+ and CD8+ IFNγ+ T cells were detected in the peripheral blood of RV-infected children 
and adults48,49. IFNγ producing T cells were also observed following experimental vaccines in animals and asso-
ciated with disease protection21,50,51. It was previously shown that IFNγ inhibit RV entry into Caco2 cells20. In our 
study, we found that human IFNγ significantly reduced RV replication, suggesting that IFNγ can inhibit RV infec-
tion at various steps of the life cycle in the infected cells. It was suggested that IFNγ responses critically determine 
the severity of RV diseases in children52.
ISGs are the ultimate effectors of IFN-mediated antiviral responses. Based on our findings, all three types 
of IFNs effectively induced a panel of well-known anti-viral ISGs both in Caco2 cells and in human organoids. 
However, further studies are needed to identify specific anti-RV ISGs to improve our understanding of immunity 
against RV infections. In conclusions, our study describes the role of both endogenous and exogenous IFN in RV 
infection, as well as the role of both basal and activated IFN signaling in limiting RV infection. These knowledge 
shall contribute to the better understanding of RV-host interactions and therapeutic development.
Material and Methods
Reagents. Type I human recombinant IFN alpha 2a (IFNα; Thermo Scientific) and IFN beta 1a (IFNβ; 
Sigma-Aldrich; Catalog Number 14151); Type II IFN gamma (IFNγ; BioLegend; Catalog# 570202), and Type 
III IFNs IL29 (IFNλ1; Abnova), IL28A (IFNλ2; Abnova) and IL28B (IFNλ3; Abnova) were dissolved in cul-
ture medium. Stocks of Jak inhibitor I (Santa Cruz Biotech, CA) was dissolved in DMSO (Sigma-Aldrich, St 
Louis, MO, USA) with a final concentration of 5 mg/mL. Anti-STAT1 antibody (#9172) was purchased from 
Cell Signaling Technology. IRF9 antibody was obtained from LSBio (Life Span BioSciences, Inc). β-actin and 
STAT2 (sc-476) antibodies were purchased from Santa Cruz Biotechnology. Anti-rabbit or anti-mouse IRDye-
conjugated antibodies were used as secondary antibodies for western blotting (Stressgen, Victoria, BC, Canada).
Viruses. Simian RV SA11, a broadly used laboratory strains, was employed. SA11 RV used in this study was 
prepared as described previously53. RV genome copy numbers were determined by quantitative real-time poly-
merase chain reaction (qRT-PCR). A plasmid template was used to generate a standard curve by plotting the log 
copy number versus the cycle threshold (CT) as previously described33.
Human-derived RV strains (G1P[8]) were obtained from fecal samples of four RV patients and stored at 
−80 °C freezer (the Erasmus MC Biobank, Department of Viroscience, Erasmus Medical Center, Rotterdam). 
These samples were collected during diarrhea period and tested negative for enterovirus, parechovirus, norovirus 
genogroup I and II, adenovirus, astrovirus and sapovirus by qRT-PCR. The patient characteristics were shown in 
Supplementary Table S1.
Cell and human primary intestinal organoid culture. Caco2 cell line (human caucasian colon adeno-
carcinoma ECACC) was cultured in Dulbecco’s modified Eagles’s medium (DMEM; Lonza, Verviers, Belgium) 
containing 20% (vol/vol) heat-inactivated fetal calf serum (FCS; Sigma-Aldrich, St. Louis USA), 100 U/mL peni-
cillin and streptomycin (Gibco, Grand Island, USA). The cells were maintained in 5% CO2 at 37 °C in a humidified 
incubator.
Organoid culture was performed as described previously33. Briefly, intestinal tissues taken from biopsy were 
vigorously shaken in 8 mM EDTA for 15 min at 4 °C. The EDTA solution was then discarded. Loosened crypts 
were collected by pipetting the solution up and down for 8–10 times through a 10 mL pipette and transferred into 
a 50 mL tube (Greiner Bioone, the Netherlands). The biopsies were repeatedly used for crypts collection (2–3 
times). Crypt suspensions were pooled and centrifuged at 300 g for 5 min. The crypt pellets were resuspended in 
2 mL complete medium containing growth factors CMGF-: advanced DMEM/F12 supplemented with 1% (vol/
vol) GlutaMAX™ Supplement (Gibco, Grand island, USA), 10 mM HEPES. The crypts were collected by centrif-
ugation at 130 g for 5 min at 4 °C, suspended in matrigel (Corning, Bedford, USA) and placed in the center of a 
24-well plate (40 μL per well). After the matrigel had solidified (15 min at 37 °C), organoids were maintained in 
culture medium at 37 °C, 5% CO2. Culture medium was refreshed every 2–3 days, and organoids were passaged 
every 6–7 days.
Inoculation of SA11 and human-derived RV strains and treatment. Caco2 cells cultured in T75 
flask were suspended and subsequently seeded into 48-well plate (5 * 104 cells/well) in DMEM complemented 
with 20% (vol/vol) FCS and 100 IU/mL penicillin-streptomycin. After 2–3 days of culture, culture medium 
was removed when the cell confluence was about 80%. The cell layers were then washed twice with 500 μL PBS. 
Serum-free DMEM medium (100 μL) containing 5 μg/mL of trypsin (Gibco, Paisley, UK) and SA11 RV were 
added and incubated for 60 min at 37 °C with 5% CO2 to allow efficient infection, followed by four times wash-
ing with PBS (500 μL each) to remove free virus particles. Subsequently, culture medium containing 5 μg/mL of 
trypsin (and indicated treatments) were added to the infected cells and incubated for 24 or 48 hours at 37 °C with 
5% CO2.
For organoid infection, SA11 RV (contain 5000 genome copies) was first activated with 5 μg/mL of trypsin at 
37 °C with 5% CO2 for 30 minutes. Subsequently, organoids were infected with the activated SA11 for 60 minutes 
at 37 °C with 5% CO2, followed by four times washing with PBS to discard the free viruses. Organoids were then 
aliquoted into 48-well plates that have been coated with 20% (vol/vol) Collagen R Solution (SERVA, Heidelberg, 
Germany) and maintained in culture medium containing indicated treatments at 37 °C with 5% CO2.
Quantitative real-time polymerase chain reaction (qRT-PCR). Total, intracellular or extracellular 
(secreted) RNA was isolated by using the Machery-NucleoSpin RNA II kit (Bioke, Leiden, The Netherlands) and 
quantified by a Nanodrop ND-1000 spectrophotometer (Wilmington, DE, USA). cDNA was made from total 
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RNA using a cDNA Synthesis Kit (Takara Bio Inc, Shiga, Japan) with random hexamer primers. qRT-PCR of 
RV RNA and genes of interest were performed with a SYBRGreen-based real-time PCR (MJ Research Opticon, 
Hercules, CA, USA) according to the manufacturer’s instructions with the StepOnePlus System (Thermo Fisher 
Scientific Life Sciences). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as a housekeeping 
gene to normalize (relative) gene expression using the 2−ΔΔCT formula. All primers used in this study are listed 
in Supplementary Table S2.
Lentiviral vector production and transfection assays. Lentiviral pLKO knockdown vectors (Sigma–
Aldrich) targeting STAT1, STAT2 and IRF9 or scrambled control, were obtained from the Erasmus Center of 
Biomics. All shRNA sequences are listed in Supplementary Table S3. The lentiviral vectors were produced in 
human embryonic kidney epithelial cell line HEK 293 T cells as previously described54. The shRNA vectors 
exerting optimal gene knockdown were selected. To generate the gene knockdown cells, Caco2 cells were trans-
duced with the lentiviral vectors and subsequently selected by adding puromycin (8 μg/mL; Sigma) to the culture 
medium. Knockdown and control Caco2 cells were infected with RV as previously described.
IFN production bioassay. The IFN production bioassay was performed to detect secreted IFN proteins 
in the culture medium as described previously55. Briefly, the culture (conditioned) medium derived from con-
trol and SA11-infected Caco2 cells (48 hours) were collected and filtered through 0.45 μm pore size membrane. 
Two luciferase reporter models which are extremely sensitive to IFN treatments were employed. Huh7.5-ET-Luc 
luciferase model is a hepatitis C virus (HCV) replicon (I389/NS3–3V/LucUbiNeo-ET) in which the HCV-related 
firefly luciferase activity (HCV-luc) can be potently inhibited by a low concentration of IFN-α treatments. 
Huh7-ISRE-luc is a luciferase reporter model in which the firefly luciferase gene was driven by multiple 
IFN-stimulated response elements (ISRE) promoter. In this model, the firefly luciferase activity can be potently 
stimulated by a low concentration of IFN-α treatment. Therefore, these two luciferase models can be employed 
to sensitively detect the presence of IFN proteins in the conditioned medium. Huh7 HCV-luc and ISRE-luc cells 
were cultured in DMEM supplemented with 10% FCS (vol/vol), 100 U/mL penicillin and streptomycin. For Huh7 
HCV-luc, 250 μg/mL G418 (Sigma-Aldrich) was added to the culture medium.
Western blot assay. Cultured cells were lysed in Laemmli sample buffer containing 0.1 M dithiothreitol 
(DTT) and heated for 5 min at 95 °C. Cell lysates were subjected to 10% sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) for 100 min running at 110 V. The proteins were transferred onto polyvinylidene 
difluoride (PVDF) membrane (Immobilon-FL) for 1.5 hours with an electric current of 250 mA. Subsequently, 
the membrane was blocked with a mixture of 2.5 ml of blocking buffer (Odyssey) and 2.5 ml of PBS containing 
0.05% Tween 20 for 1 hour at room temperature. This was followed by an overnight incubation with the indicated 
primary antibody (1:1000 dilution) at 4 °C. The membrane was then washed three times, followed by incubation 
for 1 hour with IRDye-conjugated secondary antibody (1:5000 dilution) at room temperature. After washing 
three times, the protein bands were detected with the Odyssey 3.0 Infrared Imaging System. The intensity of the 
immunoreactive bands of blotted proteins was quantified by the Odyssey V3.0 software.
Immunofluorescence microscope assay. Caco2 cells were seeded on glass coverslips. After SA11 infec-
tion for 48 hours, cells were washed with PBS, fixed in 4% PBS-buffered formalin for 10 mins and blocked with 
tween-milk-glycine medium (PBS, 0.05% tween, 5 g/L skim milk and 1.5 g/L glycine). Samples were incubated 
with anti-rotavirus (ab181695) antibody (Abcam) overnight at 4 °C. Subsequently, samples were incubated with 
1:1000 dilutions of Alexa FluorTM 594 goat anti-mouse secondary antibodies (Invitrogen). Nuclei were stained 
with DAPI (4,6-diamidino-2-phenylindole; Invitrogen). Images were detected using immunofluorescence 
microscope.
MTT assay. 10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) was 
added to Caco2 cells seeded in 96-well plates at indicated time points. The cells were incubated at 37 °C with 5% 
CO2 for 3 hours. The culture medium was then removed and 100 μl of dimethyl sulfoxide (DMSO) was added to 
each well. The absorbance of each well was read on the microplate absorbance readers (BIO-RAD) at wavelength 
of 490 nm.
Study Approval. Human intestinal tissue were obtained during surgical resection. A written informed con-
sent was signed by the volunteers or patients who agreed to participate. The study was approved by the Medical 
Ethical Committee of the Erasmus Medical Center (Medisch Ethische Toetsings Commissie Erasmus MC), and 
all experiments were performed in accordance with relevant guidelines and regulations.
Statistical Analysis. Statistical analysis was performed using the nonpaired, nonparametric test 
(Mann-Whitney test; GraphPad Prism software, GraphPad Software Inc., La Jolla, CA). P values < 0.05 were 
considered statistically significant.
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